News & Updates
Filter by Specialty:
Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor
The glucagon-like peptide-1 receptor agonist (GLP-1 RA) efpeglenatide affords cardiovascular and renal protection that is not explained by concurrent use of a sodium-glucose co-transporter-2 (SGLT2) inhibitor in patients with type 2 diabetes (T2D), according to an exploratory analysis of AMPLITUDE-O.
Cardiorenal benefit with investigational GLP-1 RA independent of concurrent SGLT2 inhibitor
30 Nov 2021
Remnant cholesterol tied to CVD death in patients with T2D, CKD, diabetic nephropathy
Remnant cholesterol (C) appears predictive of mortality due to cardiovascular disease (CVD) among patients with type 2 diabetes (T2D), chronic kidney disease (CKD) stage 3 to 5, and incident diabetic nephropathy (DN), suggests a study.
Remnant cholesterol tied to CVD death in patients with T2D, CKD, diabetic nephropathy
29 Nov 2021
Add-on ezetimibe helps reduce LDL-C in post-ACS patients
The addition of ezetimibe to a statin led to reductions in low-density lipoprotein-cholesterol (LDL-C) in patients who have been stabilized after the presentation of an acute coronary syndrome (ACS), according to data presented at AHA 2021.
Add-on ezetimibe helps reduce LDL-C in post-ACS patients
29 Nov 2021
No causal link between COVID-19 and atrial fibrillation
Patients with the coronavirus disease 2019 (COVID-19), even those genetically predisposed to the disease, are not at increased risk of developing atrial fibrillation, and vice versa, a study has found.
No causal link between COVID-19 and atrial fibrillation
29 Nov 2021
Which amino acids are associated with cardiovascular events?
A recent study has recognized alanine and glutamine as new amino acids that appear to increase the risk of coronary artery disease (CAD) and reduce the hazard of ischaemic stroke, respectively.
